The State Street SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Fri, January 16, 2026 at 1:06 PM UTC Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the ...

Payable Mar 24; for shareholders of record Mar 24; ex-div Mar 24. More on Direxion Daily S&P Biotech Bear 3X ETF LABD: ETF To Benefit From Downturns In The Biotech Industry Seeking Alpha’s Quant ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.